Pfizer secures FDA approval for expanded use of Xalkori cancer drug
The drug’s use has been expanded to treat patients with advanced, or metastatic, NSCLC whose tumors have an ROS-1 gene alteration, which is believed to lead to abnormal
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.
That’s why researchers at Hennepin County Medical Center (Minneapolis, Minn.) and the University of Minnesota are launching an innovative, comprehensive study in collaboration with Abbott (NYSE: ABT) to